Introduction - Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products - page 13

current thinking about the future of both concepts in the context of OIP testing, and
Chap. 14 provides a series of concluding statements that refl ect the current position
concerning both concepts. The topic also contains a glossary of abbreviations and
acronyms in common usage in connection with OIP testing, together with an index
of keywords to aid in searching the text.
References
1. Bonam M, Christopher D, Cipolla D, Donovan B, Goodwin D, Holmes S, Lyapustina S,
Mitchell J, Nichols S, Petterson G, Quale C, Rao N, Singh D, Tougas T, Van Oort M, Walther
B, Wyka B (2008) Minimizing variability of cascade impaction measurements in inhalers and
nebulizers. AAPS PharmSciTech 9(2):404-413
2. Mitchell JP, Nagel MW (2003) Cascade impactors for the size characterization of aerosols
from medical inhalers: their uses and limitations. J Aerosol Med 16(4):341-377
3. Rudolph G, Köbrich R, Stahlhofen W (1990) Modeling and algebraic formulation of regional
aerosol deposition in man. J Aerosol Sci 21(S1):S403-S406
4. Heyder J, Svartengren MU (2002) Basic principles of particle behavior in the human respira-
tory tract. In: Bisgaard H, O'Callaghan C, Smaldone GC (eds) Drug delivery to the lung.
Dekker, New York, NY
5. Christopher D, Curry P, Doub B, Furnkranz K, Lavery M, Lin K, Lyapustina S, Mitchell J,
Rogers B, Strickland H, Tougas T, Tsong Y, Wyka B (2003) Considerations for the develop-
ment and practice of cascade impaction testing including a mass balance failure investigation
tree. J Aerosol Med 16:235-247
6. Van Oort M, Roberts W (1996) Variable stage-variable volume strategy for cascade impaction.
In: Dalby RN, Byron PR, Farr EJ (eds) Respiratory drug delivery-V. Interpharm Press, Buffalo
Grove, IL, pp 418-421
7. Dunbar C, Mitchell JP (2005) Analysis of cascade impactor mass distributions. J Aerosol Med
18(4):439-451
8. European Directorate for the Quality of Medicines and Healthcare (EDQM) (2012)
Preparations for inhalation: aerodynamic assessment of fi ne particles, Chapter 2.9.18. In:
European Pharmacopeia, 7th edn. Strasbourg, France
9. United States Pharmacopeial Convention (USP) (2012) Aerosols, metered-dose inhalers, and
dry powder inhalers USP35-NF30, Chapter 601. Rockville, MD
10. Mitchell JP, Dolovich MB (2012) Clinically relevant test methods to establish in vitro equiva-
lence for spacers and valved holding chambers used with pressurized metered dose inhalers
(pMDIs). J Aerosol Med Pulm Deliv 25(4):217-242
11. Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, Lyapustina S
(2009) Improved quality control metrics for cascade impaction measurements of orally inhaled
drug products (OIPs). AAPS PharmSciTech 10(4):1276-1285